Agenus Inc. (AGEN) Friday announced new data from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic Colorectal cancer, that is not microsatellite instability-high or MSS or deficient mismatch repair.
The updated Phase 1 data show a 71 percent overall survival or OS rate at 12 months and a 62 percent OS rate at 18 months.
In 77 patients with refractory MSS-CRC without active liver metastases, the overall response rate was 23 percent.
The Phase 2 trial has completed participant enrollment, and the company plans to discuss the interim results with the FDA. Agenus said it and is preparing to present comprehensive Phase 2 effectiveness results, highlighting response duration and the most recent Phase 1 survival data at a major medical conference in the second half of 2024.
The company plans to submit a Biologics License Application for BOT/BAL in refractory MSS CRC later this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.